# OCS catalysts: Oculis Holding AG PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ocs/catalysts

> Oculis Holding AG (OCS) has 3 upcoming catalysts. The next is the licaminlimab primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Oculis Holding AG |
| Ticker | OCS (Nasdaq) |
| SEC CIK | 1953530 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ocs |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 5, 2024 | [Oculis Holding AG FDA approval](https://sec-api.dev/companies/ocs/catalysts) | OCS |  | completed, approved | "For example, on January 5, 2024, the FDA approved Florida's Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000095017025068021/ocs-ex99_4.htm)) |
| Jun 2024 | [Licaminlimab topline data readout](https://sec-api.dev/pdufa/licaminlimab) | OCS | signs and symptoms of moderate to severe DED | completed, positive | "In June 2024, we announced positive topline results from the Phase 2b RELIEF study evaluating Licaminlimab as a treatment for moderate-to-severe DED in which Licaminlimab was well tolerated, similar to vehicle." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_4.htm)) |
| January 6, 2025 | [OCS-05 topline data readout](https://sec-api.dev/pdufa/ocs-05) | OCS |  | completed, met | "ZUG, Switzerland, January 6, 2025 - Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results with OCS-05 in the Phase 2 ACUITY trial, which met the primary endpoint of safety and achieved statistical significance on several key efficacy-based secondary endpoints." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000095017025002044/ocs-ex99_1.htm)) |
| Q4 2025 | [Licaminlimab trial start](https://sec-api.dev/pdufa/licaminlimab) | OCS |  | scheduled | "We plan to initiate PREDICT-1, a registrational trial with a genotype-based approach to investigate Licaminlimab in DED in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000119312525274212/ocs-ex99_2.htm)) |
| Q2 2026 | [OCS-01 trial start](https://sec-api.dev/pdufa/ocs-01) | OCS |  | scheduled | "We are excited about several key developments: OCS-01 eye drops Phase 3 in DME with anticipated readout in Q2 2026, the initiation of a first in class registrational trial with Licaminlimab in precision medicine for DED, and, very importantly, we are thrilled with our positive discussions with the U.S. Food and Drug Administration (FDA), which paved the way to accelerate Privosegtor development in key unmet medical needs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000119312525274212/ocs-ex99_3.htm)) |
| April 2, 2026 | [Dexamethasone ophthalmic suspension (ocs-01) primary completion](https://sec-api.dev/pdufa/dexamethasone-ophthalmic-suspension-ocs-01) | OCS | Diabetic Macular Edema | completed | "NCT06172257 (A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06172257)) |
| April 10, 2026 | [Dexamethasone ophthalmic suspension (ocs-01) primary completion](https://sec-api.dev/pdufa/dexamethasone-ophthalmic-suspension-ocs-01) | OCS | Diabetic Macular Edema | completed | "NCT05066997 (A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-04-10 (ACTUAL); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05066997)) |
| Jun 2026 | [OCS-01 topline data readout](https://sec-api.dev/pdufa/ocs-01) | OCS | DME planned for 2026 | scheduled | "The decrease in research and development expenses was primarily due to a decrease in external service provider expense driven by the DIAMOND-1 and DIAMOND-2 trials of OCS-01 in DME, which are approaching topline readout in June 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000119312526216741/ocs-ex99_1.htm)) |
| Jun 2026 | [Oculis Holding AG topline data readout](https://sec-api.dev/companies/ocs/catalysts) | OCS |  | scheduled | "During the three months ended March 31, 2026 and 2025, the decrease in research and development expenses was primarily due to a decrease in external service provider expense driven by the impending conclusion of the DIAMOND-1 and DIAMOND-2 trials in DME, with topline results expected in June 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000119312526216741/ocs-ex99_2.htm)) |
| late 2026 | [OCS-01 topline data readout](https://sec-api.dev/pdufa/ocs-01) | OCS |  | scheduled | "As 2025 was characterized by operational excellence and transformation, 2026 is planned as a year of landmark accomplishments, with major registrational milestones anticipated: the DIAMOND-1 and DIAMOND-2 trials readout with OCS-01 in DME anticipated in June, the PREDICT-1 trial results for Licaminlimab in DED planned around late 2026, and the initiation of the PIONEER program trials." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_2.htm)) |
| Q4 2026 | [OCS-01 NDA/BLA submission](https://sec-api.dev/pdufa/ocs-01) | OCS | DME planned for 2026 | scheduled | "If the results are positive, we plan to submit a new drug application ("NDA") to the FDA for OCS-01 for the treatment of DME in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000119312526216741/ocs-ex99_2.htm)) |
| Q4 2026 | [Licaminlimab topline data readout](https://sec-api.dev/pdufa/licaminlimab) | OCS | Dry Eye Disease (DED) | scheduled | "After a successful FDA meeting in the first quarter of 2025, we initiated the PREDICT-1 registrational Phase 2/3 trial with a genotype-based approach to investigate Licaminlimab in DED in the fourth quarter of 2025 for which topline results are expected in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_4.htm)) |
| Q4 2026 | [Oculis Holding AG topline data readout](https://sec-api.dev/companies/ocs/catalysts) | OCS |  | scheduled | "Topline results from the PREDICT-1 trial are anticipated in the fourth quarter of 2026; and (iii) Privosegtor, a novel neuroprotective agent with potential broad applicability in multiple neurodegenerative diseases in ophthalmology, neuro-ophthalmology and neurology, which we are initially developing as a potential treatment for ON and NAION." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_4.htm)) |
| December 2026 | [Licaminlimab primary completion](https://sec-api.dev/pdufa/licaminlimab) | OCS | Dry Eye Disease (DED) | scheduled | "NCT07548632 (A Clinical Study Evaluating Licaminlimab for Dry Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07548632)) |
| December 2027 | [Privosegtor primary completion](https://sec-api.dev/pdufa/privosegtor) | OCS | Optic Neuritis | scheduled | "NCT07623668 (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07623668)) |
| Dec 2027 to Mar 2028 | [Privosegtor topline data readout](https://sec-api.dev/pdufa/privosegtor) | OCS | Optic Neuritis | scheduled | "NCT07623668 (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07623668)) |

## Drugs

- [Dexamethasone ophthalmic suspension (ocs-01)](https://sec-api.dev/pdufa/dexamethasone-ophthalmic-suspension-ocs-01): Diabetic Macular Edema
- [Licaminlimab](https://sec-api.dev/pdufa/licaminlimab): signs in moderate to severe ded, signs and symptoms of moderate to severe ded, Dry Eye Disease (DED)
- [OCS-01](https://sec-api.dev/pdufa/ocs-01): dme planned for 2026, dme planned for 2h 2026, diabetic macular edema
- [OCS-05](https://sec-api.dev/pdufa/ocs-05): 
- [Privosegtor](https://sec-api.dev/pdufa/privosegtor): Optic Neuritis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ocs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OCS catalysts: Oculis Holding AG PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ocs/catalysts

```bibtex
@misc{secapidev_companies_ocs_catalysts_20261116,
  title        = {OCS catalysts: Oculis Holding AG PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ocs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ocs_catalysts_20261116","title":"OCS catalysts: Oculis Holding AG PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ocs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
